
    
      The study will include multiple cohorts of patients. In the first cohort, patients may have
      previously received treatment with hypomethylating agents such as azacitidine. In later
      cohorts, prior treatment with this class of anti-cancer agents will be excluded. Later
      cohorts will include patients that are receiving this class of agents, specifically
      azacitidine, for the first time.
    
  